SecBot SecBot
Biotech Drug Report Generated Nov 16, 2026

ABV-1505

ABVC·ABVC BIOPHARMA, INC.
NEUTRAL
Drug Impact Rating3/10
Trial phase
Phase 2 (completed)
Time to market
At least 4-6 years away, if ever. The drug has completed Phase II but has not yet initiated a Phase III trial, which typically takes 2-4 years to complete, followed by FDA review. ABVC's financial constraints also pose a significant hurdle to funding late-stage development.
Why 3/10
No hard dated catalyst (PDUFA, pivotal readout, or AdComm) is scheduled for ABV-1505 in the next ~12 months. The drug has completed Phase II but has not advanced to Phase III, and no regulatory submission is pending. The impact score reflects the absence of a near-term binary event.
Actionable Insight NEUTRAL

ABV-1505 has completed Phase II testing for adult ADHD with positive signals, but no Phase III trial has been initiated and no regulatory filing is scheduled. The next meaningful catalyst would be a Phase III start announcement or a partnership expansion, neither of which is currently dated. ABVC's financial fragility (recent dilutive convertible note, going concern risk) means any clinical progress depends on securing additional funding.

Price Chart

Loading chart...

Executive Summary

ABV-1505 is a plant-based (botanical) drug candidate being developed by ABVC BioPharma (NASDAQ: ABVC) for adult ADHD. Its active ingredient, PDC-1421, is an extract from the herb Polygala tenuifolia. The drug completed Phase II testing at UCSF, showing statistically significant improvement on ADHD rating scales versus placebo with a favorable safety profile. ABVC licensed ABV-1505 (along with ABV-1504 for depression) to Xinnovation Therapeutics for the Chinese market in August 2023. However, no Phase III trial has been initiated, no regulatory submission is pending, and no registered ClinicalTrials.gov record was found for this specific drug. ABVC is a micro-cap company (~$0.91/share, ~$28M market cap) with zero product revenue, a going concern warning, and recent dilutive convertible note financing, making ABV-1505 a high-risk, early-stage asset with no near-term binary catalyst.

How It Works

ABV-1505 is a plant-based (botanical) drug candidate whose active ingredient, PDC-1421, is an extract from Polygala tenuifolia, a herb used in traditional Chinese medicine. It is being developed as a non-stimulant treatment for adult ADHD. The exact mechanism is not fully characterized but is thought to involve modulation of neurotransmitter systems in the brain, similar to how some antidepressants work, but derived from a natural plant source rather than being a synthetic chemical.

Trial Status

ABV-1505 completed Phase II Part I clinical trial at UCSF (results presented at the 2023 APSARD Conference). Phase II Part II was planned with sites in the US and Taiwan, but no completion announcement has been made. The company has stated the drug showed statistically significant improvement on ADHD rating scales vs placebo and was well tolerated with no serious adverse events. No Phase III trial has been initiated, and no ClinicalTrials.gov record was found for ABV-1505 specifically.

The Two-Sided Case

▲ Bull Case4
ABV-1505 is a plant-based (botanical) ADHD candidate derived from Polygala tenuifolia, which completed Phase II testing at UCSF showing statistically significant improvement on ADHD rating scales vs placebo with a favorable safety profile and no serious adverse events.
The drug has secured US and Taiwanese patents for PDC-1421, providing intellectual property protection. It was also licensed to Xinnovation Therapeutics for the Chinese market in August 2023, with potential for milestone payments and royalties.
Institutional investors showed accumulation in Q3 2026: Vanguard added 52% to its position, UBS doubled its stake, and State Street added 25%, signaling some institutional interest despite the company's small size.
ABVC's licensing-based business model generated $1.27M in Q3 2025 licensing revenue from multiple partners, demonstrating some ability to monetize its pipeline without direct sales.
▼ Bear Case4
ABVC is a micro-cap with zero product revenue, a going concern warning, and a recent $3.39M dilutive convertible note financing (Nov 2026) that creates future dilution risk for the ~$28M market cap company.
No Phase III trial has been initiated for ABV-1505, and no registered ClinicalTrials.gov record was found for this specific drug, suggesting development has stalled or is moving very slowly since the Phase II Part I completion in 2020.
The ADHD treatment market is crowded with established generics (amphetamine salts, methylphenidate) and branded non-stimulants (Strattera, Intuniv), making it difficult for a botanical extract to gain commercial traction even if approved.
ABVC's stock has fallen ~70% over the past 12 months (from $3.06 to $0.91), reflecting ongoing investor skepticism about the pipeline and finances.

Upcoming Catalysts

  • No hard dated catalysts are scheduled. Potential future catalysts include: announcement of Phase III trial initiation, update on Xinnovation Therapeutics licensing milestones, or additional partnership/licensing deals for the Chinese or other markets.

Source Filing

The SecBot filing or press-release report that triggered this drug report:

ABVC BIOPHARMA, INC. 424B4 ABVC ·Originating report

Sources · 6

Hover a chip for the title
1 markets.financialcontent.com2 seekingalpha.com3 theglobeandmail.com4 aol.com5 wreg.com6 nasdaq.com